OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offering

Core Viewpoint - OKYO Pharma has appointed Leerink Partners as the new sales agent for its At-The-Market (ATM) equity offering, transitioning from B. Riley Securities, to enhance its financial flexibility and support ongoing clinical development [2][3][4]. Group 1: Appointment of Sales Agent - OKYO Pharma Ltd has transitioned its ATM equity offering facility to Leerink Partners, replacing B. Riley Securities as the exclusive sales agent [2][3]. - Leerink Partners will facilitate the sale of common shares directly into the market at prevailing prices, depending on market conditions and company discretion [3]. Group 2: Purpose and Benefits of ATM Facility - The ATM facility is designed to provide OKYO Pharma with the flexibility to raise capital opportunistically while minimizing market disruption [4]. - The CFO of OKYO Pharma emphasized that this transition enhances financial flexibility to support ongoing clinical development and corporate objectives without committing to a fixed equity raise [5]. Group 3: Financial Terms - Leerink Partners will receive a commission of 3% of gross proceeds from any shares sold under the ATM program [6].